Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBT Margin (2018 - 2025)

Historic EBT Margin for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to 27.87%.

  • BioNexus Gene Lab's EBT Margin rose 232200.0% to 27.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.05%, marking a year-over-year decrease of 151200.0%. This contributed to the annual value of 16.77% for FY2024, which is 99200.0% up from last year.
  • Per BioNexus Gene Lab's latest filing, its EBT Margin stood at 27.87% for Q3 2025, which was up 232200.0% from 27.26% recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's EBT Margin peaked at 12.9% during Q2 2024, and registered a low of 99.18% during Q3 2023.
  • Its 5-year average for EBT Margin is 11.83%, with a median of 3.51% in 2024.
  • In the last 5 years, BioNexus Gene Lab's EBT Margin tumbled by -965700bps in 2023 and then surged by 480900bps in 2024.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's EBT Margin stood at 6.07% in 2021, then tumbled by -174bps to 4.49% in 2022, then soared by 349bps to 11.16% in 2023, then tumbled by -250bps to 16.72% in 2024, then plummeted by -67bps to 27.87% in 2025.
  • Its EBT Margin stands at 27.87% for Q3 2025, versus 27.26% for Q2 2025 and 29.17% for Q1 2025.